ABUS Arbutus Biopharma Corporation
Healthcare$4.64+6.67%ClosedMarket Cap: $916.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.24
P/S
4.49
EV/EBITDA
5.35
DCF Value
$-2.75
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
80.8%
Net Margin
84.0%
ROE
129.3%
ROA
58.0%
ROIC
56.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $179.1M | 100.0% | $169.1M | $169.7M | $— | — |
| Q4 null | $1.1M | 99.0% | $-7.6M | $-3.8M | $— | — |
| FY null | $14.1M | 97.4% | $-27.1M | $-33.5M | $— | — |
| Q3 null | $529.0K | 97.9% | $-8.3M | $-7.7M | $— | — |
| Q2 null | $10.7M | 100.0% | $1.5M | $2.5M | $— | — |
| Q1 null | $1.8M | -407.9% | $-34.7M | $-24.5M | $— | — |
| Q4 null | $1.6M | -459.7% | $-13.9M | $-12.5M | $— | — |
| FY null | $6.2M | 100.0% | $-76.3M | $-69.9M | $— | — |
| Q3 null | $1.3M | 100.0% | $-21.4M | $-19.7M | $— | — |
| Q2 null | $1.7M | 100.0% | $-21.6M | $-19.8M | $— | — |
| Q1 null | $1.5M | 100.0% | $-19.4M | $-17.9M | $— | — |
| Q4 2023 | $2.1M | -718.8% | $-20.7M | $-19.3M | $-0.11 | — |